Ancora Advisors, LLC Editas Medicine, Inc. Transaction History

Ancora Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $2,284 - $3,747	-325 Reduced 81.25%	75 $0
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $2,816 - $5,526	-200 Reduced 33.33%	400 $8,000
Q1 2022 May 13, 2022	BUY	$14.08 - $27.63 $2,816 - $5,526	200 Added 50.0%	600 $25,000
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $5,310 - $8,114	-200 Reduced 33.33%	400 $11,000
Q1 2021 May 14, 2021	SELL	$39.71 - $90.58 $3,971 - $9,058	-100 Reduced 14.29%	600 $25,000
Q4 2020 Feb 12, 2021	SELL	$27.07 - $84.35 $2,707 - $8,435	-100 Reduced 12.5%	700 $49,000
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $7,400 - $13,736	400 Added 100.0%	800 $24,000
Q1 2020 May 14, 2020	BUY	$14.88 - $32.78 $5,952 - $13,112	400 New	400 $8,000
Q4 2018 Feb 15, 2019	SELL	$18.19 - $31.79 $72,760 - $127,160	-4,000 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$27.65 - $38.39 $110,600 - $153,560	4,000 New	4,000 $127,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Ancora Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Ancora Advisors, LLC with notifications on news.